Milestone Scientific's CompuFlo and Director of Clinical Affairs Dr. Mark Hochman Featured on eHealth Radio Network
LIVINGSTON, NJ -- (Marketwired) -- 06/29/17 -- Milestone Scientific Inc . (NYSE: MLSS) Director of Clinical Affairs, Mark Hochman, D.D.S, a world authority on computerized injection technology, was interviewed by the eHealth Radio Network and the Dental Care & Health News Channels. The Company's CompuFlo® Epidural Instrument mentioned in the segment received FDA clearance on June 12, 2017.
Dr. Mark Hochman discussed topics related to advanced painless injections and the technology behind it, called DPS Dynamic Pressure Sensing Technology™ and its benefits for patients including:
- There is a full range of drug delivery applications across more than 20 indications, including dental injections, epidural injections, intra-articular injections and cosmetic injections, among others;
- Safety advantages - backed up by 65 million successful injections to date;
- Pressure and fluid flow rate regulation at the needle tip to substantially eliminate pain perception versus the traditional syringe;
- Real time pressure sensing to measure tissue density, in order to accurately identify the location of the needle for precise targeting.
The eHealth Radio Network reports serving a listener audience of 77,000 with approximately 3,900 site visits per day. The full interview is available at: https://ehealthradio.podbean.com/e/advanced-painless-injection-technology-with-dr-marc-hochman
Dr. Mark Hochman, has served as Director of Clinical Affairs and Director of Research and Development for Milestone Scientific since 1999. He has a Doctorate of Dental Surgery with advanced training in multiple specialties in dentistry. He formally held a part-time faculty appointment as a clinical associate professor at NYU School of Dental Surgery for over ten years and he remains an active international lecturer on a variety of topics. He is recognized as a world authority on Advanced Drug Delivery Systems, having published numerous scientific articles in this area, and is credited for developing several new injection techniques using these innovative technologies. Dr. Hochman has been responsible for inventing and contributing to the development of much of the cutting-edge innovations from Milestone Scientific, he is the primary inventor for over 20+ patents and continues to advance the art and science of subcutaneous drug delivery systems.
About Milestone Scientific Inc.
Milestone Scientific Inc. (MLSS) is a leading medical research and development company that designs and patents innovative injection technologies. Milestone's computer-controlled systems are designed to make injections precise, efficient, and virtually painless. For more information please visit our website: www.milestonescientific.com.
Safe Harbor Statement
This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues, timing of regulatory approvals and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions, future business decisions and regulatory developments, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2016. The forward looking statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.
David Waldman or Natalya Rudman
Crescendo Communications, LLC
Source: Milestone Scientific, Inc.
Released June 29, 2017